Ranbaxy Laboratories Limited has submitted an Investigational New Drug (IND) application to the Drug Controller General of India for permission to initiate phase-I human clinical trials. The IND application is for the respiratory inflammation candidate that the joint GSK-Ranbaxy steering committee had identified earlier last year.
The details can be read here.
No comments:
Post a Comment